Press Release: Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Dow Jones11-08

to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax$(R)$ will qualify for a biodefense Priority Review Voucher $(PRV.UK)$ or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R) . Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-third-quarter-2024-financial-results-302299437.html

SOURCE SOLIGENIX, INC.

/CONTACT: Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief Financial Officer, (609) 538-8200 | www.soligenix.com, Soligenix, Inc., 29 Emmons Drive, Suite B-10, Princeton, NJ 08540

(END) Dow Jones Newswires

November 08, 2024 07:30 ET (12:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481174389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481174389","market":"hk","top_or_hot":-1,"title":"Press Release: Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nto the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax<a href=\"https://laohu8.com/S/R\">$(R)$</a> will qualify for a biodefense Priority Review Voucher <a href=\"https://laohu8.com/S/PRV.UK\">$(PRV.UK)$</a> or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R) . Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the \"SEC\"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. \n</p>\n<p>\n      View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-third-quarter-2024-financial-results-302299437.html \n</p>\n<p>\n     SOURCE SOLIGENIX, INC. \n</p>\n<p>\n       /CONTACT: Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief Financial Officer, (609) 538-8200 | www.soligenix.com, <a href=\"https://laohu8.com/S/SNGX\">Soligenix, Inc.</a>, 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 08, 2024 07:30 ET (12:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax$(R)$ will qualify for a biodefense Priority Review ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNGX","symbol_name":"Soligenix, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481174389","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481174389","pubTimestamp":1731069000,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"PRINCETON, N.J., Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2024.\"We remain focused on multiple clinical activities and upcoming milestones, including the initiation of our confirmatory Phase 3 placebo-controlled study evaluating HyBryte  in the treatment of early-stage cutaneous T-cell lymphoma  before yearend,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. Additionally, we are set to initiate a Phase 2 study for SGX945  in Behet's disease shortly, with top-line results expected in the first half of 2025, which will be accompanied by data readout from our ongoing SGX302  Phase 2 study in mild-to-moderate psoriasis in the first half as well.\". Dr. Schaber continued, \"With approximately $9.8 m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNGX":"Soligenix, Inc.","BK4168":"多种金属与采矿","BK4588":"碎股","BK4099":"汽车制造商","BK4232":"货物陆运","R":"瑞德系统","TM":"丰田汽车","IDR":"Idaho Strategic Resources Inc","03160":"华夏日股对冲","BK4022":"陆运","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4555":"新能源车"},"translate_title":"新闻稿：Soligenix公布近期成就和2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03160":0.6,"IDR":0.6,"R":0.6,"SNGX":0.6,"TM":0.6},"content_text":"to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax$(R)$ will qualify for a biodefense Priority Review Voucher $(PRV.UK)$ or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R) . Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the \"SEC\"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. \n\n\n      View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-third-quarter-2024-financial-results-302299437.html \n\n\n     SOURCE SOLIGENIX, INC. \n\n\n       /CONTACT: Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief Financial Officer, (609) 538-8200 | www.soligenix.com, Soligenix, Inc., 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 07:30 ET (12:30 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481174389"}